TCR2 Therapeutics (TCRR) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Sandler Starts TCR2 Therapeutics (TCRR) at Overweight
August 12, 2020 4:43 AM EDTPiper Sandler analyst Tyler Van Buren initiates coverage on TCR2 Therapeutics (NASDAQ: TCRR) with a Overweight rating and a price target of $35.00.
For an analyst ratings summary and ratings history on TCR2 Therapeutics... More
